Although treatment options for atopic dermatitis (AD) and alopecia areata (AA) exist, some patients experience inadequate response or intolerable adverse effects (AEs) that often negatively impact ...
In a meta-analysis, topical Janus kinase (JAK) inhibitors demonstrated promising but non-significant results for vitiligo, with patients administered JAK inhibitors having a higher likelihood of ...
Ruxolitinib cream is the first FDA-approved JAK inhibitor for skin repigmentation in people with vitiligo, paving the way for additional oral and topical JAK inhibitors to treat this autoimmune ...
JAK inhibitors like baricitinib, ritlecitinib, and brepocitinib show promise in treating alopecia areata, with baricitinib approved by FDA and EMA. Baricitinib significantly reduced SALT scores at 24 ...
Higher doses of a novel Janus kinase inhibitor were associated with improved response over 24 weeks in a cohort of patients with alopecia areata, according to a study. Brett King, MD, PhD, of the ...
Leveraging advanced spatial proteomics, scientists have identified the JAK/STAT pathway as a critical target for treating toxic epidermal necrolysis, offering new hope for patients with this ...
The Janus kinase/signal transducer and activator of transcription (JAK-STAT) pathway comprises four JAK kinases and seven STAT transcription factors. Among the latter, STAT3 is the best-known oncogene ...
First patient dosed in Phase I/II HEMA-MED clinical trial (NCT06887803) evaluating the tolerability and efficacy profile of roginolisib (PI3Kδ inhibitor) plus ruxolitinib in myelofibrosis (MF) ...
Rheumatoid arthritis (RA) is an autoimmune disease, meaning it’s caused by an overactive immune system. Instead of just attacking harmful viruses and bacteria, an immune system with RA attacks your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback